How Trump’s FDA nominee may change the agency
Gaining insight into the views of Scott Gottlieb, President Donald Trump’s pick for commissioner of the Food and Drug Administration (FDA), doesn’t take much digging, as he’s been a contributor to Forbes for years on health policy.
His topics ranged from criticizing the Affordable Care Act (ACA) to arguing in March 2016 why then-candidate Trump’s proposals to lower pharmaceutical prices wouldn’t work.
In another article, he addressed how the agency, for which he worked from 2005 to 2007, could adapt its review process for new areas like gene editing and cell therapy. In the process, he offered a critique of the FDA’s regulatory process that may guide his thinking in reshaping the agency.
“It needs to be much more risk-based,” he wrote. “Right now, FDA is often too easily distracted by attractive areas like iPhone apps that nonetheless pose relatively low risks and could be ably addressed by other regulatory agencies.”
Read the full collection of his articles below:
John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.